Donate

Press News Releases

17/09/2024NEWS SHOPPER “Bexley mum with Von Hippel-Lindau celebrates victory over new drug”
5/09/2024VHL UK/Ireland “Game-Changing Drug, Belzutifan (Welireg), Recommended with Managed Access for Von Hippel-Lindau Patients in England”
5/09/2024NHS ENGLAND “First ever drug approved for NHS patients with life-threatening genetic, tumour-causing disease”
5/09/2024THE TIMES “Drug gives patients with rare tumour-causing disease hope at last”
5/09/2024NICE WIREDGOV “Adults with Von Hippel-Lindau disease to benefit from new treatment”
5/09/2024BRAIN TUMOUR RESEARCH “New treatment for rare disease that causes brain tumours”
5/09/2024Pharmaceutical Technology “NHS England offers MSD belzutifan for von Hippel-Lindau disease”
6/09/2024Nation Health Executive NHE “NICE makes two landmark approvals”
5/09/2024Action Kidney Cancer *Belzutifan available on the NHS for patients with VHL disease”
9/10/2023Scottish Medicines Consortium “belzutifan (Welireg®) is accepted for use within NHSScotland”
9/10/2023VHL UK/Ireland “SMC Approval of belzutifan(Welireg) for selected VHL Patients”
9/10/2023Action Kidney Cancer “SMC approves belzutifan for VHL kidney cancer in Scotland”
9/10/2023European Pharmaceutical Review “MSD medicine accepted for use in Scotland”
9/10/2023Samedan Pharmaceutical Publishers “MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland”
9/10/2023pharmaphorum “Scotland first in Europe to back MSD drug for VHL tumours”
7/04/2009EXPRESS “I want to save my girls from genetic timebomb”
VHL UK/Ireland
Powered by  GDPR Cookie Compliance (opens in a new tab)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.